RecruitingNCT07345494

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Sponsor

Ascendis Pharma A/S

Enrollment

50 participants

Start Date

Feb 18, 2026

Study Type

OBSERVATIONAL

Conditions

Hypoparathyroidism

Summary

The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.

Eligibility

Sex: FEMALEMin Age: 15 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Palopegteriparatide for people with hypoparathyroidism. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 15 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.